modelImatinib_1
Extends from Pharmacolibrary.Drugs.ATC.L.L01EA01_1.
Information
| name: | Imatinib_1 | |
| ATC code: | L01EA01_1 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 174 | L |
| clearance: | 11.6 | L/hr |
| other parameters in model implementation | ||
Imatinib is a tyrosine kinase inhibitor used as standard of care for chronic myeloid leukemia and gastrointestinal stromal tumors.
Pharmacokinetics
Alternative pharmacokinetic model in healthy volunteers after single oral administration.
References
Menon-Andersen, D, et al., & Barrett, JS (2009). Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer chemotherapy and pharmacology 63(2) 229–238. DOI:10.1007/s00280-008-0730-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/18398615
Widmer, N, et al., & Buclin, T (2006). Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. British journal of clinical pharmacology 62(1) 97–112. DOI:10.1111/j.1365-2125.2006.02719.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/16842382
Golabchifar, AA, et al., & Rouini, MR (2014). Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia. Cancer chemotherapy and pharmacology 74(1) 85–93. DOI:10.1007/s00280-014-2473-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24817601
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)